

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 45/06, A61P 35/00</b>		<b>(11) International Publication Number:</b> <b>WO 00/69467</b>
<b>A1</b>		<b>(43) International Publication Date:</b> 23 November 2000 (23.11.00)
<b>(21) International Application Number:</b> PCT/EP00/03407 <b>(22) International Filing Date:</b> 14 April 2000 (14.04.00) <b>(30) Priority Data:</b> 9911582.6 18 May 1999 (18.05.99) GB <b>(71) Applicant (for all designated States except US):</b> PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> DI SALLE, Enrico [IT/IT]; Viale A. Doria, 5, I-20124 Milan (IT). ZACCHEO, Tiziana [IT/IT]; Via B. Diotti 27, I-20153 Milan (IT). TEDESCHI, Michele [IT/IT]; Via Soderini 55, I-20146 Milan (IT).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>With amended claims.</i>
<b>(54) Title:</b> COMBINED METHOD OF TREATMENT COMPRISING AN AROMATASE INHIBITOR AND A FURTHER BIOLOGICALLY ACTIVE COMPOUND		
<b>(57) Abstract</b> A composition for use in breast cancer therapy in humans comprising, in amounts effective to produce a superadditive antitumour effect: (a) an antineoplastic agent in a pharmaceutically acceptable carrier and/or diluent, and (b) an aromatase inhibitor in a pharmaceutically acceptable carrier and/or diluent.		